Pre-rolls Infused with Concentrates Gain Traction in Canadian Cannabis Market
Canada’s recreational cannabis market has seen a recent boom in infused pre-rolls sales. The specialty pre-rolls are infused with cannabis concentrates, making them more potent. Consumers appear to be embracing the product according to recent sales figures. From September 2021 to September 2022, the monthly sales of infused pre-rolls grew by over 1,000 percent to approximately $12.1 million. The data comes from Headset, a cannabis analytics firm based in Seattle. According to Cooper Ashley, an analytics manager with the company, the pre-roll sales boom represents “the most significant growth of any segment within the cannabis industry over the last year or two, given that it is growing very quickly and it is also very large.”
Curaleaf Settles a Class Action Lawsuit in Oregon
Curaleaf, a multistate cannabis operator, has officially settled a class action suit in Oregon from 2021. The company agreed to settle for $100,000, which means that the approximately 500 people involved in the lawsuit will each receive about $150 to $200 depending on how many individuals file claims. The settlement does not prevent individuals from filing their own personal injury lawsuits against Curaleaf. The class action lawsuit came about after an employee at the company’s manufacturing facility mixed up two labels for products with similar identification numbers. However, one product contained THC while the other did not. Consumers purchased what they thought was a CBD wellness product, but many reported feeling unusual after ingesting drops that contained high amounts of THC.
Critics of Missouri’s Legalization Measure Say it Would Create a Monopoly
Voters in Missouri will get the opportunity to decide whether or not their state legalizes adult-use cannabis next month. However, the ballot measure is not without its critics. The state’s Democratic Party has declined to endorse the amendment. There is also expected opposition from Missouri’s Republican Governor Mike Parsons. Critics of the measure claim that the way Amendment 3 is written, it would exclude minorities and give an unfair advantage to current medical marijuana operators in the state, making it more difficult for smaller business owners and those trying to enter the market to gain access. Many fear this would create a monopoly within the state’s recreational cannabis market.
